Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today announced that following the close of the U.S. stock market on Wednesday, September 17, 2014, the Company will file financial results for the six months ended June 30, 2014 on Form 6-K with the U.S. Securities and Exchange Commission . The Form 6-K will include unaudited consolidated financial statements, as well as additional information regarding the Company.
